Associated Papers
Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma.
Meriranta L et al.
Blood Cancer Discovery, 2024
T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
Wang J et al.
Frontiers in Immunology, 2022
35572515 (PubMed )
Supplement: Table_2.xlsx › S5
Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
Guan T et al.
Frontiers in Oncology, 2022
36465410 (PubMed )
Supplement: DataSheet_1.xlsx › Supplementary_table_3
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Lee B et al.
Frontiers in Oncology, 2021
33777778 (PubMed )
Supplement: DataSheet_1.xlsx › Supplementary_Data_Set_1
Kelch-like proteins: Physiological functions and relationships with diseases.
Shi X et al.
Pharmacological Research, 2019
KLHL6 is a tumor suppressor gene in diffuse large B-cell lymphoma.
Choi J et al.
Cell Cycle (georgetown, Tex.), 2019
Loss of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing the mRNA decay factor roquin2.
Choi J et al.
Nature Cell Biology, 2018
Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.
Nadeu F et al.
Leukemia, 2018
28924241 (PubMed )
Supplement: leu2017291x1.pdf
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.
Puente XS et al.
Nature, 2011
Select a paper to view details